Product Name :PSG9 polyclonal antibody
Application_all :WB (1/500 - 1/1000), IHC (1/50 - 1/200)
Background :Pregnancy-specific beta-1-glycoprotein 9: Binds to the small latent transforming growth factor-beta complex, consisting of the N-terminal TGFB1 latency-associated peptide (LAP) and the mature form of TGFB1, thereby leading to the activation of TGFB1 . The activation of TGFB1 leads to stimulation of naive CD4(+) T-cells to increase FoxP3 expression and to an increase in the number of FoxP3(+) regulatory T-cells . Induces the differentiation of a suppressive CD4(+)LAP(+)FoxP3(-) T-cell subset . Induces the secretion of TGFB1 in macrophages, but not in activated CD4(+) T-cells . May reduce the expression of several pro-inflammatory cytokines and chemokines by CD4(+) T-cells, including IL2 and IL6
Product :1mg/ml in 0.42% Potassium phosphate, 0.87% Sodium chloride, pH 7.3, 30% glycerol, and 0.01% sodium azide.
Purification&Purity :The antibody was purified by immunogen affinity chromatography.
Storage&Stability :Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity :Recognizes endogenous levels of PSG9 protein
Note :For research use only, not for use in diagnostic procedure.
Alternative Name :PSG11; Pregnancy-specific beta-1-glycoprotein 9; PS-beta-G-9; PSBG-9; Pregnancy-specific glycoprotein 9; PS34; Pregnancy-specific beta-1 glycoprotein B; PS-beta-B; Pregnancy-specific beta-1-glycoprotein 11; PS-beta-G-11; PSBG-11; Pregnancy-specific glycoprotein 11; Pregnancy-specific glycoprotein 7; PSG7
Immunogen :A synthetic peptide encompassing a sequence within the center region of human PSG9.
Modification :Unmodification
